Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Orpea Nom.

Start price
Target price
Perf. (%)
€2.17
08.02.23
-
08.02.24
-9.35%
03.04.23

Could be very worthwhile Investment >20% year
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€1.77
21.03.23
-
21.03.24
-7.32%
02.04.23

Could be very worthwhile Investment >20% year
buy
Evotec SE

Start price
Target price
Perf. (%)
€41.50
29.11.21
-
29.11.25
-56.01%
21.03.23

Could be very worthwhile Investment >20% year
buy
Novocure Ltd

Start price
Target price
Perf. (%)
€64.20
16.03.22
€68.00
16.03.23
-6.99%
17.03.23

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€3.63
19.11.22
€2.50
19.11.23
-46.91%
11.03.23

Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Risky balance sheet
buy
Orpea Nom.

Start price
Target price
Perf. (%)
€2.58
20.02.23
-
20.02.24
-1.16%
05.03.23

Could be very worthwhile Investment >20% year
buy
Nektar Therapeutics

Start price
Target price
Perf. (%)
€2.02
23.01.23
-
23.01.24
-28.00%
03.03.23

Risky Investment
buy
Aphria Inc.

Start price
Target price
Perf. (%)
€12.71
01.03.23
€14.00
-
02.03.23

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Standard Investments for future growth
High dividend yield expected
Orpea Nom.

Start price
Target price
Perf. (%)
€2.87
05.02.23
-
05.02.24
-10.07%
18.02.23

Could be very worthwhile Investment >20% year
buy
Orpea Nom.

Start price
Target price
Perf. (%)
€2.36
07.02.23
€4.00
07.02.24
9.32%
18.02.23

Could be very worthwhile Investment >20% year
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
buy
Orpea Nom.

Start price
Target price
Perf. (%)
€5.54
01.02.23
-
01.02.24
-48.21%
05.02.23

Could be very worthwhile Investment >20% year
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€2.42
22.01.23
-
22.01.24
12.21%
05.02.23

Could be very worthwhile Investment >20% year
buy
Aphria Inc.

Start price
Target price
Perf. (%)
€12.71
21.01.23
-
24.05.24
-
26.01.23

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Standard Investments for future growth
High dividend yield expected
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€1.86
23.04.16
€18.58
22.10.24
40.44%
24.01.23

buy
Jazz Pharmaceuticals plc

Start price
Target price
Perf. (%)
€130.15
12.01.22
-
12.01.23
12.55%
13.01.23

Novocure Ltd

Start price
Target price
Perf. (%)
€68.89
02.01.23
€30.00
31.12.25
71.43%
05.01.23

Could be very worthwhile Investment >20% year
buy
Tandem Diabetes Care Inc

Start price
Target price
Perf. (%)
€136.00
28.12.21
€142.00
28.12.22
-70.42%
29.12.22

Could be worthwhile Investment >10% per year
Capable Management
Future proof or reliable business model
buy
Opko Health Inc.

Start price
Target price
Perf. (%)
€4.65
28.12.21
-
28.12.22
-75.54%
29.12.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Innovative
Future proof or reliable business model
buy
Uniqure B.V.

Start price
Target price
Perf. (%)
€19.00
27.12.21
-
27.12.22
8.55%
28.12.22

Could be worthwhile Investment >10% per year
buy
Sage Therapeutics Inc.

Start price
Target price
Perf. (%)
€37.99
27.12.21
€42.00
27.12.22
-5.05%
28.12.22

Could be worthwhile Investment >10% per year
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€2.44
17.10.22
-
17.10.23
-7.41%
22.12.22

Risky Investment
buy
Neogen Corp.

Start price
Target price
Perf. (%)
€35.40
14.12.21
€38.00
14.12.22
-59.89%
15.12.22

Could be worthwhile Investment >10% per year
buy
Horizon Pharma plc

Start price
Target price
Perf. (%)
€61.22
07.09.22
€100.00
31.12.25
73.41%
14.12.22

Could be very worthwhile Investment >20% year
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€8.47
13.12.21
-
13.12.22
-67.06%
14.12.22

Could be very worthwhile Investment >20% year
Revenue decline/stagnation expected
buy
Mirati Therapeutics Inc.

Start price
Target price
Perf. (%)
€47.20
07.12.22
-
07.12.23
-16.53%
10.12.22

Risky Investment